+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years - 72Years
All Genders
ID03190941

Gene Therapy Using Modified Peripheral Blood Lymphocytes Targeting KRAS G12V Mutation in Adults With Advanced Solid Tumors Positive for HLA-A*1101

Led by National Cancer Institute (NCI) · Updated on 2026-11-03

110

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying a new gene therapy for adults aged 18 to 72 with advanced solid tumors that express the KRAS G12V mutation and who have the HLA-A*1101 marker. This therapy involves genetically modifying a patients own white blood cells to target tumors. The study aims to evaluate the safety of this treatment and to see if it can shrink tumors in people whose cancers have progressed after standard therapies. Participants will first undergo leukapheresis to collect their peripheral blood lymphocytes, which will then be genetically modified in the lab with an anti-KRAS G12V murine T-cell receptor. Before receiving the modified cells, participants will receive a preparative chemotherapy regimen with cyclophosphamide and fludarabine over several days to prepare their body. On day 0, the modified cells will be infused back intravenously, followed by high-dose aldesleukin a drug to activate the cells administered multiple times over up to 3 days. Additional supportive care includes a drug to boost white blood cell counts and long-term antibiotics for at least six months. During the study, participants will be hospitalized for 1 to 2 weeks for recovery and monitoring with frequent lab and blood tests. Afterwards, they will have follow-up visits every few months for two years, which may include physical exams, imaging scans, blood draws, and possibly additional leukapheresis. Blood samples will be collected over several years to monitor health and treatment effects. The study measures tumor response and treatment-related side effects, with evaluations starting about six weeks after the cell infusion and continuing regularly thereafter.

CONDITIONS

Brief Title

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

Research Team

N

NCI SB Immunotherapy Recruitment Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here